Education
About Us
Working with TipRanks
Follow Us
Nephros Inc (NEPH)
NASDAQ:NEPH
NEPH Stock Chart & Stats
$5.23
<$0.01(0.48%)
At close: 4:00 PM EST
$5.23
<$0.01(0.48%)
Day’s Range― - ―
52-Week Range$1.36 - $5.98
Previous Close$1.57
Volume70.00
Average Volume (3M)75.62K
Market Cap
$55.44M
Enterprise Value$40.39M
Total Cash (Recent Filing)$5.07M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)41.9
Beta-0.29
Next Earnings
Nov 06, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding10,600,604
10 Day Avg. Volume107,933
30 Day Avg. Volume75,620
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda26.86
Forecast
1Y Price Target
$5.50Price Target Upside5.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cash PositionNephros increased its cash position to $5.1 million at the end of the second quarter, up from $3.8 million at the start of the year, with no long-term debt outstanding.
Financial PerformanceNephros reported better-than-expected financial results for their 2Q25, including revenues of $4.4 million, up 36% year-over-year, and positive net income of $237,000, or $0.02 per share.
Revenue GrowthRevenue growth in the second quarter for Nephros was fueled by record programmatic sales and a large dialysis filtration purchase order, as well as an increase in the number of active user sites.
Bears Say
Nephros News
NEPH FAQ
What was Nephros Inc’s price range in the past 12 months?
Nephros Inc lowest stock price was $1.36 and its highest was $5.98 in the past 12 months.
What is Nephros Inc’s market cap?
Nephros Inc’s market cap is $55.44M.
When is Nephros Inc’s upcoming earnings report date?
Nephros Inc’s upcoming earnings report date is Nov 06, 2025 which is in 10 days.
How were Nephros Inc’s earnings last quarter?
Nephros Inc released its earnings results on Aug 07, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.025 by $0.045.
Is Nephros Inc overvalued?
According to Wall Street analysts Nephros Inc’s price is currently Undervalued.
Does Nephros Inc pay dividends?
Nephros Inc does not currently pay dividends.
What is Nephros Inc’s EPS estimate?
Nephros Inc’s EPS estimate is -0.02.
How many shares outstanding does Nephros Inc have?
Nephros Inc has 10,600,604 shares outstanding.
What happened to Nephros Inc’s price movement after its last earnings report?
Nephros Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.025. Following the earnings report the stock price went up 34.948%.
Which hedge fund is a major shareholder of Nephros Inc?
Currently, no hedge funds are holding shares in NEPH
Nephros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (5.16% Upside)
$5.50 (5.16% Upside)
Hedge Fund Trend
Decreased
By 16.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.00%
12-Months-Change
Fundamentals
Return on Equity
15.14%
Trailing 12-Months
Asset Growth
10.30%
Trailing 12-Months
Company Description
Nephros Inc
Nephros, Inc. is a medical technology company focused on developing and commercializing innovative filtration products for the healthcare and foodservice industries. The company primarily operates in the sectors of water filtration and dialysis, offering a range of products designed to improve patient outcomes and enhance water quality. Nephros's core products include its patented ultrafilters, which are used in various applications such as hemodialysis, and its water filtration systems that cater to hospitals and healthcare facilities.
NEPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Nephros achieved its first profitable quarter and improved its gross margin and adjusted EBITDA, the company faced a decline in year-over-year revenue and cash reserves, along with regional underperformance challenges. Despite these issues, strategic initiatives and cost management have positioned Nephros for potential future growth.View all NEPH earnings summariesNEPH Stock 12 Month Forecast
Average Price Target
$5.50
▲(5.16% Upside)
Technical Analysis
Harvard Bioscience
―
Retractable Technologies
―
Milestone Scientific
―
Femasys
―
Meihua International Medical Technologies Co., Ltd.
―
Ownership Overview
2.90% Insiders
3.85% Mutual Funds
40.28% Other Institutional Investors
50.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---